Al­ny­lam's R&D up­date in­cludes 3 halts, Alzheimer's time­line and an­oth­er NASH

Al­ny­lam Phar­ma­ceu­ti­cals tout­ed its high prob­a­bil­i­ty of suc­cess in bring­ing as­sets from Phase I to Phase III — about 62% com­pared to an in­dus­try av­er­age of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.